The Business Of Biotech Podcast
Gap Analysis With Dr Pablo Valenzuela & Cristián Hernández-Cuevas
On the season finale of the Business of Biotech, we're joined by biopharma pioneer Dr. Pablo Valenzuela and a rising star in Chile's biotech scene in Cristián Hernández-Cuevas, both of Andes Biotechnologies, for a candid discussion on biopharma's compute power revolution, gap analyses and next steps for emerging biopharma, and what's driving growth in South America.
Drs. Edith Perez And Nathan Ihle: CMC Considerations For In-Human Studies
Bolt Biotherapeutics CMO Dr. Edith Perez and VP of CMC & Quality Dr. Nathan Ihle bring a unique combination of patient and production process expertise to the table for an enlightening conversation on preparing chemistry, manufacturing, and controls for an IND and ensuing first in-human studies.
Commitment To GMP With Dr. Shabbir Anik
Sutro Biopharma CTO Shabbir Anik has contributed to 15 INDs and 10 NDA’s over the course of his distinguished career. We sat down for a chat about the mechanics of GMP and CMC strategy in Sutro's effort to move its antibody conjugate, bispecific antibody, and cytokine derivative candidates forward.
Data Quality For FDA Submissions With Dr. Robert Hariri
The development of Celularity's therapies is dependent on the large-scale collection of stem cells harvested from afterbirth in maternity wards across the globe. The approach begs for FDA oversight, which is why Celularity founder Dr. Robert Hariri makes for an excellent discussion on the importance of data quality and complete master files for FDA submissions.
Dr. Gaurav Shah: Rocket's Chief Gene Therapist & Virtuoso
On this episode of The Business of Biotech, Rocket Pharmaceuticals CEO Dr. Gaurav Shah shares the parallels between his leadership in the gene therapy space and his successes as a Grammy®-nominated recording artist. Learn how Dr. Shah manages the scientific process, employees, finances, and stakeholder expectations by drawing from his mastery of music.
Dr. Randy Schatzman On Dodging Disruption: The New Fundraising Norm
Dr. Randy Schatzman, CEO at Bolt Biotherapeutics, discusses his company's adjustment to pandemic disruption on the fundraising trail. He walks us through the remote-fundraising strategy that landed Bolt's recent $93.5 million Series C financing round, and how the company is moving towards an IPO in spite of market, civil, and political tumult.
Myeloid Cells, Transplants, & Immuno-Oncology Inspiration
OSE Immunotherapeutics CEO Alexis Peyroles joins The Business Of Biotech: Summer Executive Sessions to discuss myeloid cells' role in immunology, why a team of transplant specialists is key to his company's therapeutic development approach, and creating differentiation as a clinical-stage immunotherapy company in an ever-growing sea of competitors.
Arrowhead Pharma's Dr. Christopher Anzalone: Taking RNAi Beyond The Liver
Arrowhead Pharma CEO Christopher Anzalone, Ph.D. gives us the inside story on the stake his company claimed on the now re-burgeoning RNAi space, the indications his company is targeting beyond liver disease, and how it's addressing the development and process challenges that must be overcome to further progress RNAi beyond the liver.
Immunomedics' Dr. Loretta Itri On Taking ADCs Across The Finish Line
While Immunomedics CMO Loretta Itri, M.D. is no stranger to taking drugs across the commercial finish line in big pharma, her most recent win with TRODELVY was very, very different. Here, Dr. Itri shares insight on her small biopharma's first commercial launch, the manufacturing and regulatory challenges overcome to get there, and why ADCs are coming of age.
Building A Biotech Around Your Therapeutic Platform
With the science behind Heat Biologics' platform to activate immune responses against pathogenic or cancer antigens in place, founder and CEO Jeff Wolf proceeded to structure the organization in a strategic fashion to support that platform. On this episode of The Business Of Biotech: Summer Executive Sessions, Wolf tells us how he did it.
Solving The COVID-19 Workforce Crisis
Obsidian Therapeutics CEO Dr. Paul Wotton didn't let pandemic-induced workforce restrictions impede his biopharma's progress. On this episode, Wotton tells us how a homegrown software application, dubbed SWFT, was built, how it's working, and why Obsidian has made it available to more than 30 (and growing) other biotechs, free of charge.
Bringing Big-League Finance Experience To An Emerging Biotech
The Business Of Biotech "Summer Executive Sessions" kick off with Athersys CFO Ivor Macleod, who brings finance leadership experience at Roche and Merck to Athersys as the company readies its lead candidate for life beyond clinical trials. Learn how Macleod applies big-league finance principles to an emerging biopharma company.
Leaving The Incubator With Kavitha Iyer Rodrigues
A strategic departure from the biotech incubator requires the coordination of moving parts aplenty. Development timelines, seed funding, facilities development, and team dynamics are just a sampling of the critical aspects discussed here with multi-time founder and Zumutor Biologics CEO Kavitha Iyer Rodrigues.
Episode 6: Building An All-Star Biotech Team With Vivek Ramaswamy
Roivant Sciences is parent company to some 20 emerging biopharma entities with dozens of candidates in their collective pipelines. Founder Vivek Ramaswamy shares practical and applicable advice on the people, positions, and characteristics that constitute a winning biopharma team, and best practices for recruiting and retaining them.
Episode 5: Finding Funding In Volatile Times With Ben Zeskind
This week's Business Of Biotech pod features Immuneering CEO Dr. Ben Zeskind, who launched his biotech on the back of creative financing in the throes of the Great Recession. A pivot into biopharma at the outset of the COVID-19 pandemic landed Immuneering a $20 million series A round to develop its pipeline.
Episode 4: Building Your Pitch With Leslie Williams
Leslie Williams is a multi-time biotech founder and board member who's honed her pitch-building skills to a fine point. On this episode of The Business Of Biotech, Williams shares best practices for building your pitch deck, how to draw out the nuance that makes your story unique, what to expect in your initial pitch session and follow-on meetings, and why the human element trumps everything else in an otherwise formulaic pitch process.
Episode 3: The Biopharma Exit Strategy With Dr. Francois Nader
On this episode of The Business Of Biotech, we talk with Dr. Francois Nader—a man who's orchestrated several wildly successful biotech exits—about why it's imperative to begin with the end in mind as you create value for stakeholders, and how to navigate your options when the time to exit is right.
Episode 2: The Business Of Biotech: Allan Shaw
Few are better suited to advise emerging biopharma leaders on the building blocks of biotech than Allan Shaw. On this episode of The Business Of Biotech, we'll absorb Shaw's to-the-point, practical advice on winning finances, building a pitch, assembling a biotech all-star team, leaving the incubator, navigating early regulatory considerations, and more.
Episode 1: Introducing The Business Of Biotech Podcast
With the support of Cytiva, formerly GE Healthcare Life Sciences, we're launching a podcast to serve as a resource for the leaders of new and emerging biopharmas. We have an incredible group of guests—all of them founders who have taken biotherapy ideas and successfully turned them into clinical realities—lined up to share their insight with you. Here’s how the series, which is focused on the financial, organizational, HR, process, and regulatory aspects of launching a biopharma company, will play out.
THE BUSINESS OF BIOTECH
Hosted by BioProcess Online Chief Editor Matt Pillar, The Business of Biotech brings you weekly intelligence and inspiration from leading voices in the biopharma industry. Created exclusively for the leaders of new and emerging biopharma firms, The Business of Biotech tackles organizational, funding, HR, regulatory, and CMC considerations with insight from peer founders who have taken biologic therapies from an idea to clinical success. The Business of biotech is graciously supported by Cytiva, formerly GE Health Care Life Sciences.